Ovarian Cancer
Consolidation therapy with paclitaxel is effective in ovarian cancer
Published in Women's Health Weekly, March 4th, 2004
"According to a study from the United States, "The administration of 'consolidation' therapy is designed to maximize the benefits achieved from primary chemotherapy, to both improve progression-free and overall survival.
"Paclitaxel is an excellent agent to consider for a consolidation strategy in ovarian cancer, based on its activity in the disease, its cycle-specificity, and the lack of serious cumulative toxicity (except for neuropathy)," wrote M. Markman and colleagues, Cleveland Clinic Foundation, Department of Hematology and Medical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Osteoporosis
Women with short stature may be more prone to vertebral fractures - Stroke
Lifetime risk higher for women, those with high blood pressure - Colon Cancer
Estrogen may have protective effect, study finds - Endometrial Cancer
ERT poses little recurrence risk for women treated for early-stage disease - Hormone Replacement Therapy
HRT can benefit women with menopausal symptoms, harm those without - Pain Medicine
Menstrual symptoms and pain overlap in women with irritable bowel syndrome - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
